In this edition:
A novel B7H3 ADC in heavily pretreated CRPC
ARCHES: 5-year OS analysis of enzalutamide + ADT in metastatic hormone-sensitive prostate cancer
Predictive utility of PTEN activity signatures as a biomarker for OS
Pasritamig in metastatic CRPC
VIOLET: [161Tb]Tb-PSMA-I&T in previously-treated metastatic CRPC
AMPLITUDE: niraparib + AAP in HRR-altered metastatic castration-sensitive prostate cancer
TALAPRO-2: benefit according to HRR alteration subgroup
BULLSEYE: [177Lu]Lu-PSMA-617 in oligo-metastatic hormone-sensitive prostate cancer
COMRADE: olaparib + radium-223 in CRPC with bone metastases
EVOLUTION: [177Lu]Lu-PSMA-617 + ipilimumab + nivolumab in metastatic CRPC
Please login below to download this issue (PDF)